Antonio Cipriani

Innovative Research Within Haemophilia Treatment ✨🩸       Our groundbreaking research efforts at Novo Nordisk have led us to a novel VHH-based FVIIIa-mimetic molecule, currently in pre-clinical development, aiming to transform haemophilia A (HA) treatment. Our goal? To create the first oral HA treatment, potentially eliminating the need for injections and thereby reducing the treatment burden.      Through extensive protein engineering and formulation, the team has achieved ultra-high potency with a small molecular size, demonstrating oral availability, and a prolonged systemic half-life. What all this breaks down to is that we are making progress toward enabling a once-daily oral treatment for HA.      The recognition of our team’s abstract presented at the 2024 International Society on Thrombosis and Haemostasis (ISTH) highlights session is a testament to our commitment to innovating haemophilia treatment. We are proud to be at the forefront of such innovative research aimed at delivering novel treatments for the haemophilia community.     Congratulations to the research team! Jacob Lund; Jais Rose Bjelke; Daniele Granata; Thomas Egebjerg; Eva Johansson; @Wang Zhuoran; Pierre-Louis Bardonnet; pingping chen; Mads Bjelke; Andreas Vegge    #HaemophiliaResearch #DrivingChange #ISTH2024 

186

6 Kommentarer

Bone Marrow Cancer Treatment Under Review: Medicinrådet Reevaluates Lenalidomide Recommendation After Disappointing Real-World Results The Danish Medicines Council (Medicinrådet) is reassessing its recommendation for lenalidomide (Revlimid by Bristol Myers Squibb) as a maintenance therapy for bone marrow cancer following a Danish real-world study that revealed significantly lower effectiveness than anticipated. The study found that lenalidomide did not improve overall or progression-free survival and led to a high rate of treatment discontinuation due to adverse side effects. This unexpected outcome contrasts with the positive results from earlier clinical trials and has prompted Medicinrådet to reconsider the drug's viability as a long-term therapy. A final decision, balancing patient outcomes and healthcare sustainability, is expected later this year. For more details please click the link! https://lnkd.in/dcw2Zs4e #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

1

The results from this very recent Nordic survey (n=4000) on the knowledge and attitudes towards HIV/AIDS in the era of undetectable = untransmissible was presented last week at the Nordic HIV & Virology Conference in Stockholm. This poster won the Poster Award. The reason is because it shows that ... 51% claim being informed about HIV/AIDS and 71% agree HIV is a manageable chronic disease, still 40% believe transmission is possible under ART, 22% and 9% respectively still believe it is transmissible by kissing or sharing itmes such as plates or glasses! KNOWLEDGE and breaking entrenched (false) believes are probably the most important factors in eleviating stigmas...and it seems we still have some way to go. These data can help get the facts right and help improve awareness, education, and policies. #GileadNordics #MyCompany Janniche Hammer Susanne von Stockenström Juha Vuorte Ellen Moseholm Larsen Aurelie Miglar, Ph.D. Philippa Collins

24

Jump! Novo Nordisk Overtakes Tesla in AI Innovation 🚀 It's early to say, but Novo Nordisk "jumped" to become a frontrunner in Pharma AI innovation based on the momentum they're currently having. To save you some time, I've researched and summarized key points about their activities so that more companies can benefit and jump into the AI world. This project, a collaboration with NVIDIA, is centered at the Danish Centre for AI Innovation. The Gefion supercomputer, equipped with NVIDIA H100 Tensor Core GPUs, is designed to process large datasets quickly, accelerating the identification of new drug candidates and addressing environmental challenges. Key Features: 1. Drug Discovery and Healthcare: The supercomputer will expedite the development of treatments, including new obesity medications like Wegovy and innovative insulin therapies. 2. Green Transition: AI capabilities will optimize energy use and support sustainable technologies, aligning with Denmark's environmental goals. 3. Infrastructure and Data Security: Gefion boasts significant computational power, housed in a secure facility ensuring data sovereignty and compliance with Danish regulations. I believe more pharma and biotech companies should jump into AI and Partnerships with technology companies as there could be a massive combined advantage for patients. Yes, there is uncertainty, and it may not immediately overtake Tesla, but let's jump together. #AI #Innovation #Healthcare #GreenTransition #NovoNordisk #TechInnovation For more details, check the sources: https://lnkd.in/dniZ8TBP https://lnkd.in/d_y4Bbqb https://lnkd.in/debgthuY

28

1 Kommentar

Our CSO Vlad Seitan, PhD is in Sweden at the ISCT, International Society for Cell & Gene Therapy 2024 European Regional meeting in Gothenburg 4-6 September. Come along to his talk “Leveraging miRNAs for the design of cell therapies programmed with conditional gene silencing”: Thursday 5 September  13.45-14.45  Session: New Frontiers in Genetic Engineering Approaches: A Biological Recipe to Gene-Modified Cell Therapies.  The panel session is chaired by Vincenzo Di Cerbo, PhD, Cell and Gene Therapy Catapult, with speakers including Benjamin Klapholz, PhD, bit.bio, and Luke Pase, Anocca, alongside Vlad. Over the past decade, the successful application of genetic engineering tools augmenting cellular properties or correcting DNA mutations has paved the way to the development of groundbreaking ex vivo and in vivo cell and gene therapies. However, the complexity of these products is a barrier to a consistent and controllable manufacturing. The session, we will explore how combining deep understanding of the biological systems with innovative cellular engineering strategies is addressing the quest of developing the next-generation of affordable therapies. In his talk title Vlad will discuss present our progress with our uniquely powerful gene-silencing technology and how it can help in the creation of next-generation programmable advanced therapies. For the full agenda see - https://lnkd.in/e5DXJ2_R We are open to meeting collaborators and partners and investors – catch Vlad at the conference or get in touch via email at [email protected] #cellandgenetherapy #genesilencing #advancedtherapies #drugdiscovery  

22

1 Kommentar

Insmed announced positive topline results from landmark ASPEN study of Brensocatib in patients with bronchiectasis. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed for the treatment of patients with bronchiectasis, CRSsNP, and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Brensocatib is an investigational drug product that has not been approved for any indication in any jurisdiction. Chemenu has been working to develop more compounds for drug discovery. Here comes the building blocks we can provide: https://lnkd.in/gyvaMQ9P #Brensocatib #AZD7986 #INS1007 #DPP1 #bronchiectasis #buildingblocks

1

A recent decision by EMA will have significant reimbursement implications for Novo Nordisk’s Wegovy (semaglutide) in Germany. Besides obesity, the company had applied for a separate indication for the drug to reduce the risk of major heart and circulation problems in adults with a history of serious cardiovascular disease (such as a heart attack, stroke or poor blood flow to the limbs) and a body mass index (BMI) of 27 kg/m2 or greater.   The drug was already licensed for use in adults who have: • a BMI of 30 kg/m² or greater (obesity) or; • a BMI of at least 27 kg/m² but less than 30 kg/m² (overweight) who have weight-related health problems (such as diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea or a history of heart attack, stroke or blood vessel problems).   At a meeting on 26th July, the CHMP concluded that “the use of Wegovy in this group of people is already covered by the approved indication for weight management in people with a BMI of 27 kg/m2 or greater. Therefore, no separate indication for the prevention of cardiovascular disease in people with obesity and overweight is needed.” The drug’s product information will, however, be updated to include the study results submitted for the application so that healthcare professionals have access to up-to-date data on the effects of Wegovy in people with established cardiovascular disease and a BMI of 27 kg/m2 or greater.   EMA’s decision contrasts with that taken by the FDA in March, following priority review, to approve Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. John Sharretts, Director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research, said: “Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight. ... Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health.”   The position taken by EMA means Wegovy will continue to be excluded from public reimbursement in Germany—Europe’s largest pharmaceutical market. In March, the GBA confirmed Wegovy’s status under the terms of the Sozialgesetzbuch V (Social Code V) as a “lifestyle drug,” meaning that it is legally excluded from statutory health insurance reimbursement. The committee rejected calls to introduce special regulations for Wegovy on account of “the increased risk of the occurrence of accompanying and secondary illnesses.” I'm running a LinkedIn poll on contracting approaches that could expand access to innovative treatments for common chronic disorders such as obesity that would potentially have a major budget impact. Please share your thoughts at tinyurl.com/c7xbnzx7. #EMA #FDA #Wegovy #obesity #reimbursement #Germany

207

18 Kommentarer